L26/P-328 Menstrual blood supports non-invasive longitudinal tracking of reproductive tract microbiome dynamics
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y. Wang und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Can menstrual blood (MB) serve as a reliable, non-invasive tool to monitor reproductive tract microbiome stability and change? Summary answer MB longitudinal sampling captures a Lactobacillus-dominant microbiome with low cycle-to-cycle variability (r = 0.99) and sensitive detection of 0.1% genus-level changes in physiological shifts and dysbiosis. What is known already Microbiome imbalance of the female reproductive tract, including reduced Lactobacillus dominance and enrichment of anaerobic genera has been associated with adverse reproductive outcomes, including infertility and recurrent implantation failure. Current clinical assessment relies primarily on vaginal swabs or invasive endometrial sampling. Vaginal swabs may not reflect endometrial microbial communities, while endometrial sampling is unsuitable for frequent monitoring. MB contains endometrial tissue, blood, and uterine secretions and represents a potential non-invasive biospecimen and reflection of the uterine microenvironment. However, its microbiome profile, temporal stability, and ability to quantify microbiome imbalance across cycles remain insufficiently characterised. Study design, size, duration Exploratory prospective longitudinal cohort study designed to enrol up to 50 reproductive-age participants followed across up to 5 menstrual cycles over 12 months. Up to 3 MB samples were collected on multiple days of menstruation and compared with vaginal swabs. Current pilot data from 20 participants demonstrate feasibility and inform prespecified longitudinal analyses. Participants/materials, setting, methods Participants aged 18–49 years and not using hormonal contraception self-collected MB using menstrual cups during menstruation (Days 1–4). Vaginal swabs were collected during MB collection and outside menstruation. Contamination controls included hand/environmental/cervical swabs, peripheral blood, and menstrual cups worn outside menstruation. Microbiome DNA was extracted using QIAGEN microbiome kits and profiled by Nanopore long-read 16S rRNA sequencing and qPCR. Health status was captured using participant questionnaires and commercial vaginal health testing. Main results and the role of chance Pilot data, validated by 16S rRNA sequencing and qPCR, demonstrate that MB is a reproducible, Lactobacillus-dominant biospecimen (median: 91.3%; n = 15), with Lactobacillus crispatus as the dominant species (median: 55.1%; n = 15). In healthy participants, MB exhibited alpha diversity comparable to endometrial biopsies (median Shannon index =0.6) and substantially lower than vaginal swabs (=2.1). Longitudinal sampling across 3 menstrual cycles showed that individual microbiome profiles remained highly stable (median Pearson r = 0.99, range 0.89-1.00, n = 4). In altered microbiome states, MB captured Lactobacillus species turnover and enrichment of 30 genera associated with reproductive tract infections including Gardnerella, Prevotella, Streptococcus, and Staphylococcus. MB demonstrated greater sensitivity for detecting upper-reproductive-tract infection associated with chronic endometritis, including Escherichia and Ureaplasma (100% detection rate at 0.1%–85% relative abundance), which were absent in paired vaginal swabs (n = 5). An exploratory multimetric framework combining the relative abundance of protective genera in MB, including Lactobacillus, and compositional features demonstrated stratification of microbiome profiles into healthy, transient and abnormal states. Transient states may represent an early microbiome signature before symptom onset. These pilot observations will be validated in a larger cohort to assess cycle-to-cycle and day-to-day microbiome dynamics and their temporal relationship with symptom onset. Limitations, reasons for caution Findings require validation in larger, racially diverse cohorts with conventional clinical testing. Interpretation of microbiome findings in relation to fertility outcomes is limited, as fertility status was largely unknown in this pilot cohort. Wider implications of the findings MB sampling supports scalable, non-invasive longitudinal monitoring of reproductive tract microbiome dynamics. With further validation, MB-based multimetric models may support early identification of microbiome imbalance preceding symptoms, informing personalised fertility assessment and preventive intervention. Trial registration number No
Zitieren
APA
Wang, Y., Mutter, A., Menon, A., & Hadjimitsis, A. (2026). L26/P-328 Menstrual blood supports non-invasive longitudinal tracking of reproductive tract microbiome dynamics. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.664
Vancouver
Wang Y, Mutter A, Menon A, Hadjimitsis A. L26/P-328 Menstrual blood supports non-invasive longitudinal tracking of reproductive tract microbiome dynamics. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.664
BibTeX
@article{Wang2026,
author = {Wang, Y. and Mutter, A. and Menon, A. and Hadjimitsis, A.},
title = {L26/P-328 Menstrual blood supports non-invasive longitudinal tracking of reproductive tract microbiome dynamics},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.664}
}
EUVIMED